Summary of Use during Lactation

No information is available on the use of physostigmine during breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information in nursing mothers was not found as of the revision date. In animals, cholinergic drugs increase oxytocin release,[1] and physostigmine increases serum prolactin in humans.[2,3] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1.

Clarke G, Fall CH, Lincoln DW, et al. Effects of cholinoceptor antagonists on the suckling-induced and experimentally evoked release of oxytocin. Br J Pharmacol. 1978;63:519–27. [PMC free article: PMC1668097] [PubMed: 566601]

2.

Risch SC, Janowsky DS, Siever LJ, et al. Cholinomimetic-induced co-release of prolactin and beta-endorphin in man. Psychopharmacol Bull. 1982;18:21–5. [PubMed: 6296908]

3.

Risch SC, Janowsky DS, Siever LJ, et al. Correlated cholinomimetic-stimulated beta-endorphin and prolactin release in humans. Peptides. 1982;3:319–22. [PubMed: 6289276]

Substance Name

Physostigmine

CAS Registry Number

57-47-6

Drug Class

Breast Feeding

Lactation

Cholinesterase Inhibitors

Parasympathomimetics